ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Flamma, a pharmaceutical contract development and manufacturing firm based in Bergamo, Italy, has announced a three-year, $200 million investment program. The company says it will improve a manufacturing site it acquired in Bulciago, Italy, and expand manufacturing of active pharmaceutical ingredients (APIs) at its China location from 200 m3 to 400 m3. It will also add highly potent API manufacturing at its plant in Malvern, Pennsylvania, and technologies including flow chemistry at its headquarters. The company says the expansion supports a strategy of securing domestic supply chains with the ability to transfer projects in China to Europe while pursuing API production for the Chinese market in China.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter